• Keine Ergebnisse gefunden

Supplementary Table 3. Levels of population markers. Comparison between patients and controls and patients with themselves at different times. Controls

N/A
N/A
Info
Herunterladen
Protected

Academic year: 2022

Aktie "Supplementary Table 3. Levels of population markers. Comparison between patients and controls and patients with themselves at different times. Controls"

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Jetzt herunterladen ( 1 Seite )

Volltext

(1)

Supplementary Table 3. Levels of population markers. Comparison between patients and controls and patients with themselves at different times.

Controls¢ PD-0yr¢ PD-1yr¢ PD-2yr¢

PD-0yr vs PD-1yr

PD-0yr vs PD-2yr

PD-1yr vs PD-2yr CD4 39.05[29.03-45.04] 32.09[26.25-37.82] 37.42[27.41-44.00] 40.06[29.74-44.31]

0.0395* 0.4922 0.6953 P = 0.0115+ P = 0.7451 P = 0.9770

CD8 33.75[25.96-38.63] 35.12[30.38-39.76] 30.55[29.07-34.33] 33.02[28.50-39.35]

0.1324 0.9219 0.9219 P = 0.3770 P = 0.5352 P = 0.9627

CD19 18.04[13.19-21.75] 16.77[13.08-22.68] 15.50[12.86-18.72] 19.13[14.87-23.68]

0.2247 0.7695 0.6250 P = 0.8429 P = 0.1972 P = 0.6629

¢ Data are reported as median and interquartile range [IQR]. Differences between patients and controls are shown below the median for each group. Differences between patients and themselves during the follow-up are shown in the tree last columns. PD-0yr (untreated Parkinson’s disease patients), PD-1yr (patients treated for one year), PD-2yr (patients treated for two years). (*) indicate significant differences between patient groups. (*) indicates significant differences between patients and control subjects. P < 0.05 (*); P < 0.005 (**); P < 0.0005 (***).

Referenzen

Jetzt herunterladen ( PDF - 1 Seite - 285.78 KB )

ÄHNLICHE DOKUMENTE

patients with and without coronary artery disease

1. To evaluate patients with ACS and with or without essential hypertension according to plasma Hcy level for determining 1) the prevalence of HtHcy among these subjects, 2)

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and

The goal of our study presented here was to examine the predictive value of MAPT, TOPO IIa, and HER-2 mRNA expression in breast cancer patients who received neoadjuvant

Gait patterns and mood in everyday life: A comparison between depressed patients and non-depressed controls

To this end, we computed a total of 10 multilevel models considering positive and negative affect predicting the four gait parameters (body posture, vertical up-and-down

Vision loss in patients with giant cell arteritis treated with tocilizumab.

This prospective study of 34 biopsy- proven GCA with vision loss and treatment with GC showed a deterioration of visual acuity by 2 or more lines in 27% of the patients despite GC

Supplementary Table 1: Characteristics of patients with BD compared with all patients in the RISE registry.

Total patients in RISE represents patients in RISE, aged 18 years and older, at least 2 visits with &gt;= 30 days apart during the study period with

Comparison of empathy with patients between first-year and last-year medical students at Tehran University of Medical Sciences

3- Occupational Health and Safety Research Center, Hamadan University of Medical Sciences, Hamadan, Iran 4- Mental Health Research Center, Psychosocial Health Research Institute,

Patients and methods

Patients with open fractures underwent a mean of 4.9 changes while the ones with closed fractures underwent 2.5 and those with only soft tissue injuries 2.9 procedures (p &lt;

COVID‑19 in multiple sclerosis patients treated with dimethyl fumarate

[1] reporting a case series of seven patients affected by multiple sclerosis (MS), in treatment with dimethyl fumarate (DMF), that developed a self-limit- ing SARS-CoV-2 infection